EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations

Ibrahim Turkoz, Mehmet Daskiran, Uzma Siddiqui, R Karl Knight, Karen L Johnston, Christoph U Correll

International Journal of Neuropsychopharmacology · 2024

DOI: 10.1093/ijnp/pyad067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2024. Verfasst von Ibrahim Turkoz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, LLC, Titusville, NJ, USA. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using real-world data for PP3M and PP1M and compared relapse prevention rates with PP6M from an open-label extension (OLE) study in adult patients with schizophrenia.

Methods

PP6M data were derived from a single-arm, 24-month, OLE study (NCT04072575), which included patients with schizophrenia who completed a 12-month randomized, double-blind, noninferiority, phase-3 study (NCT03345342) without relapse. Patients in the PP3M and PP1M ECAs were identified from the IBM® MarketScan® Multistate Medicaid Database based on similar eligibility criteria as the PP6M cohort.

Results

A total of 178 patients were included in each cohort following propensity score matching. Most patients were men (>70%; mean age: 39–41 years). Time to relapse (primary analysis based on Kaplan-Meier estimates) was significantly delayed in the PP6M cohort (P < .001, log-rank test). The relapse rate was lower in the PP6M cohort (3.9%) vs PP3M (20.2%) and PP1M (29.8%) cohorts. Risk of relapse decreased significantly (P < .001) by 82% for PP6M vs PP3M (HR = 0.18 [95% CI = 0.08 to 0.40]), 89% for PP6M vs PP1M (HR = 0.11 [0.05 to 0.25]), and 35% for PP3M vs PP1M (HR = 0.65 [0.42 to 0.99]; P = .043). Sensitivity analysis confirmed findings from the primary analysis. Although the ECAs were matched to mimic the characteristics of the PP6M cohort, heterogeneity between the groups could exist due to factors including prior study participation, unmeasured confounders, variations in data capture and quality, and completeness of clinical information.

Conclusions

In a clinical trial setting, PP6M significantly delayed time to relapse and demonstrated lower relapse rates compared with PP3M and PP1M treatments in real-world settings among adult patients with schizophrenia.

Trial registration

ClinicalTrials.gov Identifier: NCT04072575; EudraCT number: 2018-004532-30

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaAntipsychotic AgentsAdultMaleUnited StatesHumansFemalePaliperidone PalmitateRecurrenceSecondary Prevention

Stichwörter der Autor:innen

Paliperidone palmitate 6-monthpaliperidone palmitate 1-monthpaliperidone palmitate 3-monthreal-world datarelapse preventionschizophrenia

Substanzen

Paliperidone PalmitateAntipsychotic Agents

Autor:innen und Institutionen

  • Janssen Research & Development, LLC, Titusville, NJ, USA.
  • Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
  • Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, New York, USA.
  • Donald and Barbara Zucker School of Medicine at Hofestra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, New York, USA.
  • Charité - Universitätsmedizin, Berlin, Department of Child and Adolescent Psychiatry, Germany.

Zitieren

APA

Turkoz, I., Daskiran, M., Siddiqui, U., Knight, R. K., Johnston, K. L., & Correll, C. U. (2024). Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyad067

Vancouver

Turkoz I, Daskiran M, Siddiqui U, Knight RK, Johnston KL, Correll CU. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. International Journal of Neuropsychopharmacology. 2024. doi:10.1093/ijnp/pyad067

BibTeX
@article{Turkoz2024,
  author = {Turkoz, Ibrahim and Daskiran, Mehmet and Siddiqui, Uzma and Knight, R Karl and Johnston, Karen L and Correll, Christoph U},
  title = {Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2024},
  doi = {10.1093/ijnp/pyad067}
}
Kostenlos starten →